Aromatase inhibitors (AIs), such as Anastrozole, Letrozole and Exemestane, are the well‐known standard treatment for postmenopausal women with hormone receptor (HR)–positive early breast cancer (EBC), offering significant reductions in recurrence and improved survival outcomes [1, 2]. Here, CYP19A1 is linked to breast carcinoma.